| Autor: |
Sparidans RW; Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands. r.w.sparidans@pharm.uu.nl, Dost F, Crommentuyn KM, Huitema AD, Schellens JH, Beijnen JH |
| Jazyk: |
angličtina |
| Zdroj: |
Biomedical chromatography : BMC [Biomed Chromatogr] 2006 Aug; Vol. 20 (8), pp. 671-3. |
| DOI: |
10.1002/bmc.667 |
| Abstrakt: |
Tipranavir is the most recently introduced protease inhibitor for the suppression of the human immunodeficiency virus (HIV). A selective reversed-phase liquid chromatographic assay, previously developed for atazanavir, has been extended and validated for tipranavir in plasma. Compounds were isolated from a 500 microL plasma sample using liquid-liquid extraction with dichloromethane. After evaporation and reconstitution of the extract the sample was analysed using reversed-phase liquid chromatography and ultra violet detection at 280 nm. In the evaluated concentration range (0.2-50 microg/mL tipranavir), intra-day precisions were (Copyright 2006 John Wiley & Sons, Ltd.) |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Plný text